Mereo Cash Per Share vs Ev To Sales Analysis

MREO Stock

USD 3.73 0.04 1.06%

Mereo BioPharma financial indicator trend analysis is infinitely more than just investigating Mereo BioPharma Group recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mereo BioPharma Group is a good investment. Please check the relationship between Mereo BioPharma Cash Per Share and its Ev To Sales accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

Cash Per Share vs Ev To Sales

Cash Per Share vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mereo BioPharma Group Cash Per Share account and Ev To Sales. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Mereo BioPharma's Cash Per Share and Ev To Sales is -0.07. Overlapping area represents the amount of variation of Cash Per Share that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of Mereo BioPharma Group, assuming nothing else is changed. The correlation between historical values of Mereo BioPharma's Cash Per Share and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Per Share of Mereo BioPharma Group are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Cash Per Share i.e., Mereo BioPharma's Cash Per Share and Ev To Sales go up and down completely randomly.

Correlation Coefficient

-0.07

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cash Per Share

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from Mereo BioPharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mereo BioPharma Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

At this time, Mereo BioPharma's Issuance Of Capital Stock is very stable compared to the past year. As of the 30th of December 2024, Sales General And Administrative To Revenue is likely to grow to 1.93, while Tax Provision is likely to drop (558.6 K).

Mereo BioPharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment
Total Assets		-0.31	-0.42	-0.38	0.85	-0.37	0.24	-0.17	-0.7	0.56	-0.29	0.81	0.19	0.85	-0.34	-0.49	-0.38	-0.63	-0.12	-0.31	-0.45	-0.15	0.83	0.25	-0.44	-0.19
Short Long Term Debt Total	-0.31		0.37	0.79	-0.65	0.33	-0.23	0.68	0.86	-0.29	0.73	-0.73	0.66	-0.69	0.71	0.21	0.56	0.68	0.0	0.13	0.8	0.68	-0.67	0.56	0.04	0.68
Other Current Liab	-0.42	0.37		0.46	-0.61	0.46	0.23	-0.02	0.32	-0.82	-0.17	-0.28	-0.24	-0.3	-0.04	0.85	0.51	0.78	-0.07	0.82	0.6	0.08	-0.25	-0.26	0.71	-0.01
Total Current Liabilities	-0.38	0.79	0.46		-0.55	0.01	0.05	0.77	0.71	-0.54	0.72	-0.63	0.36	-0.64	0.62	0.45	0.16	0.69	0.01	0.44	0.53	0.81	-0.58	0.21	0.39	0.77
Total Stockholder Equity	0.85	-0.65	-0.61	-0.55		-0.69	0.37	-0.36	-0.85	0.64	-0.37	0.87	-0.12	0.89	-0.37	-0.59	-0.75	-0.77	-0.02	-0.38	-0.85	-0.35	0.87	-0.05	-0.41	-0.37
Other Liab	-0.37	0.33	0.46	0.01	-0.69		-0.58	0.02	0.42	-0.32	-0.07	-0.42	0.2	-0.4	-0.17	0.37	0.95	0.32	-0.08	0.21	0.82	0.0	-0.46	0.21	0.09	0.02
Net Tangible Assets	0.24	-0.23	0.23	0.05	0.37	-0.58		-0.11	-0.4	-0.27	-0.33	0.43	-0.5	0.38	0.07	0.3	-0.51	0.24	0.36	0.36	-0.43	-0.02	0.5	-0.52	0.47	-0.1
Property Plant And Equipment Net	-0.17	0.68	-0.02	0.77	-0.36	0.02	-0.11		0.59	-0.28	0.76	-0.51	0.51	-0.52	0.65	0.21	0.15	0.41	0.11	0.14	0.43	0.99	-0.46	0.32	0.16	1.0
Net Debt	-0.7	0.86	0.32	0.71	-0.85	0.42	-0.4	0.59		-0.31	0.77	-0.98	0.52	-0.95	0.73	0.22	0.56	0.7	0.17	0.08	0.77	0.55	-0.95	0.43	0.06	0.58
Retained Earnings	0.56	-0.29	-0.82	-0.54	0.64	-0.32	-0.27	-0.28	-0.31		0.09	0.31	0.43	0.38	-0.04	-0.99	-0.35	-0.77	0.12	-0.9	-0.48	-0.36	0.28	0.55	-0.95	-0.31
Accounts Payable	-0.29	0.73	-0.17	0.72	-0.37	-0.07	-0.33	0.76	0.77	0.09		-0.72	0.73	-0.68	0.77	-0.2	0.07	0.29	0.2	-0.23	0.36	0.72	-0.7	0.62	-0.26	0.75
Cash	0.81	-0.73	-0.28	-0.63	0.87	-0.42	0.43	-0.51	-0.98	0.31	-0.72		-0.4	0.99	-0.68	-0.22	-0.52	-0.66	-0.21	-0.05	-0.69	-0.46	0.99	-0.32	-0.08	-0.51
Non Current Assets Total	0.19	0.66	-0.24	0.36	-0.12	0.2	-0.5	0.51	0.52	0.43	0.73	-0.4		-0.31	0.48	-0.46	0.31	0.01	0.14	-0.43	0.44	0.46	-0.4	0.98	-0.65	0.49
Cash And Short Term Investments	0.85	-0.69	-0.3	-0.64	0.89	-0.4	0.38	-0.52	-0.95	0.38	-0.68	0.99	-0.31		-0.67	-0.3	-0.49	-0.66	-0.21	-0.08	-0.66	-0.48	0.98	-0.21	-0.18	-0.52
Net Receivables	-0.34	0.71	-0.04	0.62	-0.37	-0.17	0.07	0.65	0.73	-0.04	0.77	-0.68	0.48	-0.67		-0.06	0.06	0.54	0.41	-0.16	0.3	0.61	-0.6	0.37	-0.06	0.65
Common Stock Total Equity	-0.49	0.21	0.85	0.45	-0.59	0.37	0.3	0.21	0.22	-0.99	-0.2	-0.22	-0.46	-0.3	-0.06		0.37	0.72	-0.09	0.9	0.47	0.29	-0.2	-0.57	0.95	0.23
Non Current Liabilities Total	-0.38	0.56	0.51	0.16	-0.75	0.95	-0.51	0.15	0.56	-0.35	0.07	-0.52	0.31	-0.49	0.06	0.37		0.48	-0.08	0.19	0.92	0.13	-0.53	0.31	0.09	0.14
Capital Surpluse	-0.63	0.68	0.78	0.69	-0.77	0.32	0.24	0.41	0.7	-0.77	0.29	-0.66	0.01	-0.66	0.54	0.72	0.48		0.25	0.63	0.68	0.46	-0.59	-0.09	0.62	0.42
Other Current Assets	-0.12	0.0	-0.07	0.01	-0.02	-0.08	0.36	0.11	0.17	0.12	0.2	-0.21	0.14	-0.21	0.41	-0.09	-0.08	0.25		-0.15	-0.06	0.1	-0.19	0.12	-0.11	0.11
Other Stockholder Equity	-0.31	0.13	0.82	0.44	-0.38	0.21	0.36	0.14	0.08	-0.9	-0.23	-0.05	-0.43	-0.08	-0.16	0.9	0.19	0.63	-0.15		0.33	0.25	-0.04	-0.51	0.87	0.16
Total Liab	-0.45	0.8	0.6	0.53	-0.85	0.82	-0.43	0.43	0.77	-0.48	0.36	-0.69	0.44	-0.66	0.3	0.47	0.92	0.68	-0.06	0.33		0.43	-0.68	0.38	0.2	0.43
Property Plant And Equipment Gross	-0.15	0.68	0.08	0.81	-0.35	0.0	-0.02	0.99	0.55	-0.36	0.72	-0.46	0.46	-0.48	0.61	0.29	0.13	0.46	0.1	0.25	0.43		-0.41	0.26	0.24	0.99
Total Current Assets	0.83	-0.67	-0.25	-0.58	0.87	-0.46	0.5	-0.46	-0.95	0.28	-0.7	0.99	-0.4	0.98	-0.6	-0.2	-0.53	-0.59	-0.19	-0.04	-0.68	-0.41		-0.32	-0.05	-0.46
Intangible Assets	0.25	0.56	-0.26	0.21	-0.05	0.21	-0.52	0.32	0.43	0.55	0.62	-0.32	0.98	-0.21	0.37	-0.57	0.31	-0.09	0.12	-0.51	0.38	0.26	-0.32		-0.76	0.29
Common Stock	-0.44	0.04	0.71	0.39	-0.41	0.09	0.47	0.16	0.06	-0.95	-0.26	-0.08	-0.65	-0.18	-0.06	0.95	0.09	0.62	-0.11	0.87	0.2	0.24	-0.05	-0.76		0.18
Property Plant Equipment	-0.19	0.68	-0.01	0.77	-0.37	0.02	-0.1	1.0	0.58	-0.31	0.75	-0.51	0.49	-0.52	0.65	0.23	0.14	0.42	0.11	0.16	0.43	0.99	-0.46	0.29	0.18

Click cells to compare fundamentals

Mereo BioPharma Account Relationship Matchups

Mereo BioPharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	86.4M	62.9M	126.4M	88.1M	66.5M	70.1M
Short Long Term Debt Total	32.4M	17.9M	16.8M	12.8M	6.0M	5.7M
Other Current Liab	354K	8.0M	7.9M	9.4M	5.8M	5.4M
Total Current Liabilities	29.9M	8.6M	12.5M	24.7M	9.5M	14.3M
Total Stockholder Equity	40.3M	(15.0M)	88.0M	61.9M	50.5M	44.6M
Other Liab	1.6M	52.1M	9.7M	311K	357.7K	339.8K
Net Tangible Assets	(4.2M)	(46.6M)	63.4M	37.8M	43.4M	45.6M
Property Plant And Equipment Net	11.6M	1.6M	2.5M	1.8M	1.7M	2.4M
Net Debt	16.1M	(5.5M)	(77.5M)	(43.6M)	(51.5M)	(54.0M)
Retained Earnings	(146.1M)	(309.7M)	(297.0M)	(331.2M)	(419.6M)	(398.6M)
Accounts Payable	6.4M	2.9M	2.3M	3.5M	2.3M	2.8M
Cash	16.3M	23.5M	94.3M	56.3M	57.4M	55.8M
Non Current Assets Total	56.0M	33.2M	27.1M	25.9M	2.7M	2.6M
Non Currrent Assets Other	(56.0M)	(33.2M)	(27.1M)	(25.9M)	(23.4M)	(24.5M)
Long Term Debt	5.4M	16.1M	14.4M	4.4M	5.1M	4.8M
Cash And Short Term Investments	16.3M	23.5M	94.3M	56.3M	57.4M	41.0M
Net Receivables	12.0M	1.0M	1.4M	2.7M	3.7M	3.8M
Common Stock Total Equity	213.3K	213.7K	294K	1.0M	1.2M	1.2M
Common Stock Shares Outstanding	89.4M	339.0M	555.3M	603.2M	659.5M	692.4M
Short Term Investments	544K	547K	569K	51.1M	58.8M	61.7M
Liabilities And Stockholders Equity	86.4M	62.9M	126.4M	88.1M	66.5M	70.1M
Non Current Liabilities Total	16.3M	69.4M	25.9M	1.5M	6.5M	6.2M
Capital Lease Obligations	11.9M	1.8M	2.4M	1.7M	1.6M	2.4M
Inventory	(12.0M)	(4.6M)	(1.8M)	(2.7M)	1.2M	1.3M
Other Current Assets	14.1M	1.6M	5.0M	4.3M	2.6M	2.5M
Other Stockholder Equity	138.7M	294.7M	383.2M	488.1M	484.9M	273.7M
Total Liab	46.2M	77.9M	38.4M	26.2M	16.0M	15.2M
Property Plant And Equipment Gross	13.3M	1.6M	4.1M	3.4M	2.5M	3.1M
Short Long Term Debt	1.9M	6.8M	15.1M	11.1M	12.7M	6.4M
Total Current Assets	30.4M	29.7M	99.3M	62.1M	63.8M	64.2M
Accumulated Other Comprehensive Income	47.3M	133.2M	136.9M	137.9M	(17.5M)	(16.6M)
Non Current Liabilities Other	44K	62K	80K	182K	764K	802.2K
Short Term Debt	17.7M	636K	622K	11.6M	652K	619.4K
Intangible Assets	44.5M	31.6M	24.6M	24.1M	1.1M	1.0M
Common Stock	294K	1.0M	1.8M	1.9M	2.8M	2.9M
Property Plant Equipment	11.6M	1.6M	2.5M	1.8M	2.1M	2.5M
Current Deferred Revenue	(177.7K)	5.4M	8.4M	6.5M	7.4M	4.4M
Net Invested Capital	60.8M	1.2M	102.4M	73.0M	54.9M	49.1M

Pair Trading with Mereo BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mereo Stock

0.7	EQ	Equillium	Pair Corr
0.76	ME	23Andme Holding	Pair Corr
0.85	VALN	Valneva SE ADR	Pair Corr

Moving against Mereo Stock

0.82	VCEL	Vericel Corp Ord	Pair Corr
0.76	VCYT	Veracyte	Pair Corr
0.7	DRTS	Alpha Tau Medical	Pair Corr
0.57	DMAC	DiaMedica Therapeutics	Pair Corr
0.56	SABSW	SAB Biotherapeutics	Pair Corr

The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.

The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:

How To Invest In Mereo

Details

Is Mereo Stock a good investment?

Details

What is Mereo BioPharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.25)

Revenue Per Share

0.007

Return On Assets

(0.24)

Return On Equity

(0.48)

The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mereo Cash Per Share vs Ev To Sales Analysis

Cash Per Share vs Ev To Sales

Cash Per Share vs Ev To Sales Correlation Analysis

Correlation Coefficient

Cash Per Share

Ev To Sales

Mereo BioPharma fundamental ratios Correlations

Mereo BioPharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mereo BioPharma fundamental ratios Accounts

Pair Trading with Mereo BioPharma

Moving together with Mereo Stock

Moving against Mereo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant Equipment	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Property Plant Equipment	+ 0.99	Property Plant And Equipment Gross
Intangible Assets	+ 0.98	Non Current Assets Total

Common Stock Total Equity	- 0.99	Retained Earnings
Cash	- 0.98	Net Debt
Common Stock	- 0.95	Retained Earnings
Total Current Assets	- 0.95	Net Debt
Cash And Short Term Investments	- 0.95	Net Debt
Other Stockholder Equity	- 0.9	Retained Earnings